Investors Might Be Losing Patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) Increasing Losses, as Stock Sheds 5.6% Over the Past Week

Yahoo FinanceOct 30 22:29

Crinetics Pharmaceuticals: Strong Buy Recommendation Driven by Best-in-Class Efficacy and Solid Financial Position

TipRanksOct 23 05:15

State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals

Yahoo FinanceOct 18 03:09

Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024

GlobeNewswireOct 16 20:00

JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $71

Futu NewsOct 15 04:31 · Ratings

Express News | Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BreakingsOct 11 04:40